Background and aims: To evaluate serum neurofilament light chain (sNFL) levels as a biomarker for treatment efficacy in multiple sclerosis (MS) patients undergoing various disease‐modifying therapies (DMTs), focusing on extended interval dosing (EID) regimens. Here, NEFL is linked to myeloid sarcoma.